Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75204
UPID:
TM127_HUMAN
Alternative names:
-
Alternative UPACC:
O75204; D3DXH0
Background:
Transmembrane protein 127 plays a pivotal role in cellular processes by acting as a negative regulator of the TOR signaling pathway mediated by mTORC1. Its involvement in controlling cell proliferation positions it as a potential tumor suppressor.
Therapeutic significance:
Linked to Pheochromocytoma, a tumor causing abnormal catecholamine production leading to hypertension, Transmembrane protein 127's genetic variants suggest a susceptibility role. Understanding its function could pave the way for innovative treatments targeting this adrenal gland disorder.